JPRN-jRCT2080221285未知1 期
A Phase 1 Study of linifanib (ABT-869) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment
Abbott Japan Co., Ltd.0 个研究点目标入组 12 人开始时间: 2010年10月26日最近更新:
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •2. The subject must have cytologically or histologically confirmed non-squamous NSCLC
- •3. The subject must have advanced or metastatic (Stage IV [According to AJCC staging manual, 7th edition]) disease that is not amenable to surgical resection or radiation with curative intent.
- •4. The subject must have not received prior chemotherapy for NSCLC.
- •18. The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.
排除标准
- •1. The subject has hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
- •2. The subject has received any anti-cancer therapy for treatment of NSCLC including investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies, hormonal, targeted agents, biologic therapy or cytotoxic chemotherapy which includes neo-adjuvant or adjuvant chemotherapy for NSCLC.
研究者
相似试验
已完成
1 期
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT01225302AbbVie12
已完成
1 期
A Study of Lenvatinib Plus Nivolumab in Participants With HepatocellularCarcinoma, HepatocellularJPRN-jRCT2080223794Eisai Co., Ltd.26
进行中（未招募）
不适用
Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpressioPatients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breastMedDRA version: 14.1Level: LLTClassification code 10006174Term: Breast adenocarcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065348Term: Breast adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2008-000528-22-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
2 期
A phase II study of lenvatinib (E7080/MK-7902) in combination with carboplatin pemetrexed and pembrolizumab (MK-3475) for patients with pretreated advanced non-squamous non-small cell lung cancer harboring EGFR mutationsAdvanced non-squamous non-small cell lung cancer harboring EGFR mutationsJPRN-jRCT2031220147Takahashi Kazuhisa30
已完成
不适用
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)PER-035-02SCHERING PLOUGH RESEARCH INSTITUTE,